18.有關藥品引發氣喘之敘述，下列何者正確？
(A)β-blockers在氣喘病人中引發氣喘的比例很高，不論non-selective或β1-selective blockers均為氣喘病人之絕對禁忌症
(B)氣喘病人有aspirin過敏的比例在30%以下，所以NIH建議只有確知aspirin過敏史的氣喘病人須避免使用此類藥品
(C)β-blocker眼藥水不會引起氣喘病人的發作
(D)COX-2 selective NSAIDs不可使用在aspirin過敏的氣喘病人

(D)

Lack of bronchoconstriction — Unlike aspirin and some NSAIDs, selective COX-2 inhibitors appear to have little risk of precipitating bronchospasm in patients with aspirin-induced asthma

However, despite the reassuring data from clinical trials, it should be noted that the manufacturers' labeling for the coxibs in the United States includes a warning that they should not be given to patients who have experienced asthma, urticaria, or allergic reactions after taking aspirin or other NSAIDs.

Highly selective COX-2 inhibitors — Highly selective COX-2 inhibitors demonstrate at least a 200- to 300-fold selectivity for inhibition of COX-2 over COX-1 at the defined therapeutic doses. Highly selective COX-2 inhibitors are tolerated by most patients with pseudoallergic reactions to NSAIDs, with the exceptions discussed below. This option is appropriate for patients who need an anti-inflammatory agent, have had gastrointestinal toxicity with NSAIDs, or are not seeking to take aspirin for its cardioprotective effects. Selective COX-2 inhibitors include celecoxib (available worldwide), etoricoxib, parecoxib, and lumiracoxib (the latter three are not available in the United States)

ref:uptodate